Kidney function and race may change drug dosing in stem cell transplants
NCT ID NCT05534620
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 22 times
Summary
This study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 people with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatment but gathered important dosing information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
VCU Massey Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.